Back to News
Market Impact: 0.2
Milestone Enrolls First Canadian Patient In Phase 3 For Etripamil
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Milestone Pharmaceuticals announced enrollment of the first patient at a Canadian site in its Phase 3 ReVeRA-301 trial of etripamil nasal spray for atrial fibrillation with rapid ventricular response. The enrollment marks incremental progress in the company’s late-stage clinical development program, though the article provides no efficacy, safety, or financial results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
MIST0.45
More News
- Northern Star shares pop as Australian gold miner rejects $27-billion takeover proposal
- Here are the 4 big things we're watching in the stock market in the week ahead
- Paramount Warner Deal Tests Hollywood’s Future
- Healey pledges “new age of industrialisation” as Government backs British shipbuilding
- ‘China has arrived’: From $1,000 Gucci sneakers to German cars, China is coming for the industries that made Europe rich
- OpenAI, Anthropic CEOs called to appear at Australian AI probe
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Reading Conviction in the Tape: What Level 3 Order Book Data Really Tells Discretionary PMs
- AI Tools for CFA Charterholders: An Evidence Standard